Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02277444 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

A Phase 3 study of Arthritis, Juvenile, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 3
Development phase
130
Enrollment target
20
Study locations

NCT02277444 is a Phase 3 study of Arthritis, Juvenile that has completed, run by Janssen Research & Development. The registered enrollment target is 130 participants. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02277444, a Phase 3 study of Arthritis, Juvenile, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 3
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with polyarticular (affects 5 or more joints) juvenile (an onset before age 16) idiopathic (of unknown cause) arthritis (joint pain) (pJIA) manifested by greater than or equal to (\>=) 5 joints with active arthritis despite methotrexate (MTX) therapy for \>= 2 months.

Conditions Studied

Interventions

  • DRUG Methotrexate
  • DRUG Golimumab

Study Locations (20)

Other

  • - Buenos Aires
  • - Rosario
  • - San Miguel de Tucumán
  • - Botucatu
  • - Campinas
  • - Porto Alegre

Ohio

  • - Avon
  • - Cincinnati
  • - Cleveland

North Carolina

  • - Durham
  • - Hickory

California

  • - San Diego

Illinois

  • - Chicago

Massachusetts

  • - Boston

New Jersey

  • - Hackensack

New York

  • - New Hyde Park

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2014-12-22
Est. Completion 2024-09-27
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

What the Registry Record Tells You About NCT02277444

The ClinicalTrials.gov registry entry for NCT02277444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis, Juvenile appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate is the first listed.

NCT02277444 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Ohio, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02277444 about?

NCT02277444 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy". The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with polyarticular (affects 5 or more joints) juvenile (an onset before age 16) idiopat...

What is the current status of trial NCT02277444?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2014-12-22. Estimated completion is 2024-09-27.

What conditions does trial NCT02277444 study?

This clinical trial studies the following conditions: Arthritis, Juvenile.

What interventions are being tested in trial NCT02277444?

The interventions under investigation include: Methotrexate (DRUG), Golimumab (DRUG).

Who is sponsoring clinical trial NCT02277444?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02277444 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis, Juvenile

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.